Technical Spotlight: StemSation International (STSN).

2nd Resistance Point0.1333
1st Resistance Point0.1267

Fresh off a successfully reverse merger, and FINRA approved name and ticker change, StemSation International Inc OTCMKTS:STSN just announced entering to DSM industry. The company is attemping to push from the USA into other markets with their advanced stem cell system (SCS) renewal and repair and the endocannabinoid system (ECS) products.

Since the reverse merger, there is only 1.1 million in the company float, making it a ultra-low float stock. Furthermore, there is now a website launched by the company along with a number of social media sites.

Hard hitting CEO Ray Carter Jr., who was responsible for growing the company StemTech to $65 million, has announced he is now the CEO of StemSation International Inc (OTC:STSN). For over 30 years, Ray has directed growth in both private and public direct selling companies, from start-ups to Fortune 500 firms. His new company, StemSation International Inc (OTC:STSN) has just launched, and is now trading OTC Pink current under the symbol “STSN“.

Connecting to recent Stem Cell studies on COVID-19, a new report out shows that Bio-Pharm companies have shifted their focus from CX pathology systems (what has typically been for Coronovirus) to research on the effect of Stem Cell differentiation on the Corona Virus.

Chinese doctor who runs a lab in Wuhan – ground zero of the coronavirus pandemic – claims he could save thousands of lives after making a breakthrough in the treatment of the deadly pathogen, DailyMailTV can reveal. Dr. Dongcheng Wu, an expert in stem cell therapy, said he has successfully treated nine patients who were hospitalised with novel coronavirus pneumonia.

https://www.dailymail.co.uk/news/article-8116881/Doctor-claims-breakthrough-stem-cell-injections-treat-coronavirus.html

Leave a Reply

Your email address will not be published. Required fields are marked *